Immune modulations and immunotherapies for Alzheimer’s disease: a comprehensive review

References

Abbott, A. and Dolgin, E. (2016). Failed Alzheimer’s trial does not kill leading theory of disease. Nature 540: 15–16, https://doi.org/10.1038/nature.2016.21045.Search in Google Scholar

Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A.L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J.K., et al.. (2012). An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J. Neurosci. 32: 9677–9689, https://doi.org/10.1523/jneurosci.4742-11.2012.Search in Google Scholar

Aisen, P.S. (2002). The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. Lancet Neurol. 1: 279–284, https://doi.org/10.1016/s1474-4422(02)00133-3.Search in Google Scholar

Ajmone-Cat, M.A., Bernardo, A., Greco, A., and Minghetti, L. (2010). Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 3: 1949–1965, https://doi.org/10.3390/ph3061949.Search in Google Scholar

Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., et al.. (2000). Inflammation and Alzheimer’s disease. Neurobiol. Aging 21: 383–421, https://doi.org/10.1016/s0197-4580(00)00124-x.Search in Google Scholar

Alam, R., Driver, D., Wu, S., Lozano, E., Key, S.L., Hole, J.T., Hayashi, M.L., and Lu, J. (2017). Preclinical characterization of an antibody [LY3303560] targeting aggregated tau. Alzheimer’s Dementia: J. Alzheim. Assoc. 13: P592–P593, https://doi.org/10.1016/j.jalz.2017.07.227.Search in Google Scholar

Alzheimer’s Association (2016). 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dementia 12: 459–509, https://doi.org/10.1016/j.jalz.2016.03.001.Search in Google Scholar PubMed

Alzheimer’s Association (2019). 2019 Alzheimer’s disease facts and figures. Alzheimer’s Dementia 15: 321–387.10.1016/j.jalz.2019.01.010Search in Google Scholar

Armstrong, R. (2019). Risk factors for Alzheimer’s disease. Folia Neuropathol. 57: 87–105, https://doi.org/10.5114/fn.2019.85929.Search in Google Scholar PubMed

Avital, A., Goshen, I., Kamsler, A., Segal, M., Iverfeldt, K., Richter-Levin, G., and Yirmiya, R. (2003). Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus 13: 826–834, https://doi.org/10.1002/hipo.10135.Search in Google Scholar PubMed

Barrera-Ocampo, A. and Lopera, F. (2016). Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb. Méd. 47: 203–212, https://doi.org/10.25100/cm.v47i4.2640.Search in Google Scholar

Baulch, J.E., Acharya, M.M., Agrawal, S., Apodaca, L.A., Monteiro, C., and Agrawal, A. (2020). Immune and inflammatory determinants underlying Alzheimer’s disease pathology. J. Neuroimmune Pharmacol. 15: 852–862, doi:https://doi.org/10.1007/s11481-020-09908-9.Search in Google Scholar

Boche, D., Perry, V.H., and Nicoll, J.A. (2013). Review: activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 39: 3–18, https://doi.org/10.1111/nan.12011.Search in Google Scholar

Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W.F., et al.. (2012). Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J. Alzheim. Dis. 28: 49–69, https://doi.org/10.3233/jad-2011-110977.Search in Google Scholar

Bolós, M. and Perea, J.R. (2017). Alzheimer’s disease as an inflammatory disease. Biomol. Concepts 8: 37–43, doi:https://doi.org/10.1515/bmc-2016-0029.Search in Google Scholar

Boxer, A.L., Qureshi, I., Ahlijanian, M., Grundman, M., Golbe, L.I., Litvan, I., Honig, L.S., Tuite, P., Mcfarland, N.R., O’Suilleabhain, P., et al.. (2019). Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 18: 549–558, https://doi.org/10.1016/s1474-4422(19)30139-5.Search in Google Scholar

Braak, H. and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82: 239–259, https://doi.org/10.1007/bf00308809.Search in Google Scholar

Braak, H., Zetterberg, H., Del Tredici, K., and Blennow, K. (2013). Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 126: 631–641, https://doi.org/10.1007/s00401-013-1139-0.Search in Google Scholar

Brandt, R., Leger, J., and Lee, G. (1995). Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain. J. Cell Biol. 131: 1327–1340, https://doi.org/10.1083/jcb.131.5.1327.Search in Google Scholar

Buée, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P.R. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33: 95–130, https://doi.org/10.1016/s0165-0173(00)00019-9.Search in Google Scholar

Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E.M., Waldmann, H., and Mandelkow, E. (2009). Development of tau aggregation inhibitors for Alzheimer’s disease. Angew Chem. Int. Ed. Engl. 48: 1740–1752, https://doi.org/10.1002/anie.200802621.Search in Google Scholar PubMed

Burkert, K., Moodley, K., Angel, C.E., Brooks, A., and Graham, E.S. (2012). Detailed analysis of inflammatory and neuromodulatory cytokine secretion from human NT2 astrocytes using multiplex bead array. Neurochem. Int. 60: 573–580, https://doi.org/10.1016/j.neuint.2011.09.002.Search in Google Scholar PubMed

Butchart, J., Brook, L., Hopkins, V., Teeling, J., Puntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al.. (2015). Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 84: 2161–2168, https://doi.org/10.1212/wnl.0000000000001617.Search in Google Scholar

Cabezas, R., Avila, M., Gonzalez, J., El-Bachá, R.S., Báez, E., García-Segura, L.M., Jurado Coronel, J.C., Capani, F., Cardona-Gomez, G.P., and Barreto, G.E. (2014). Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front. Cell. Neurosci. 8: 211, https://doi.org/10.3389/fncel.2014.00211.Search in Google Scholar PubMed PubMed Central

Calderón-Garcidueñas, L., Reynoso-Robles, R., Vargas-Martínez, J., Gómez-Maqueo-Chew, A., Perez-Guille, B., Mukherjee, P.S., Torres-Jardón, R., Perry, G., and Gónzalez-Maciel, A. (2016). Prefrontal white matter pathology in air pollution exposed Mexico City young urbanites and their potential impact on neurovascular unit dysfunction and the development of Alzheimer’s disease. Environ. Res. 146: 404–417, https://doi.org/10.1016/j.envres.2015.12.031.Search in Google Scholar PubMed

Cardona, A.E., Huang, D., Sasse, M.E., and Ransohoff, R.M. (2006). Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat. Protoc. 1: 1947–1951, https://doi.org/10.1038/nprot.2006.327.Search in Google Scholar PubMed

Chen, M.H., Li, C.T., Tsai, C.F., Lin, W.C., Chang, W.H., Chen, T.J., Pan, T.L., Su, T.P., and Bai, Y.M. (2014). Risk of dementia among patients with asthma: a nationwide longitudinal study. J. Am. Med. Dir. Assoc. 15: 763–767, https://doi.org/10.1016/j.jamda.2014.06.003.Search in Google Scholar PubMed

Coll, R.C., Robertson, A.A., Chae, J.J., Higgins, S.C., Muñoz-Planillo, R., Inserra, M.C., Vetter, I., Dungan, L.S., Monks, B.G., Stutz, A., et al.. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21: 248–255, doi:https://doi.org/10.1038/nm.3806.Search in Google Scholar PubMed PubMed Central

Congdon, E.E. and Sigurdsson, E.M. (2018). Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14: 399–415, https://doi.org/10.1038/s41582-018-0013-z.Search in Google Scholar PubMed PubMed Central

Constantinescu, C.S., Tani, M., Ransohoff, R.M., Wysocka, M., Hilliard, B., Fujioka, T., Murphy, S., Tighe, P.J., Das Sarma, J., Trinchieri, G., et al.. (2005). Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. J. Neurochem. 95: 331–340, https://doi.org/10.1111/j.1471-4159.2005.03368.x.Search in Google Scholar PubMed

Czerkowicz, J., Chen, W., Wang, Q., Shen, C., Wager, C., Stone, I., Stebbins, C., Lamb, M., Setser, J., Cantone, G., et al.. (2017). [P4–039]: Pan-Tau antibody BIIB076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study. Alzheimer’s Dementia 13: P1271, https://doi.org/10.1016/j.jalz.2017.06.1903.Search in Google Scholar

Daniels, M.J., Rivers-Auty, J., and Schilling, T. (2016). Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat. Commun. 7: 12504, doi:https://doi.org/10.1038/ncomms12504.Search in Google Scholar PubMed PubMed Central

Dasu, M.R., Park, S., Devaraj, S., and Jialal, I. (2009). Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 150: 3457–3464, https://doi.org/10.1210/en.2008-1757.Search in Google Scholar PubMed PubMed Central

Deardorff, W.J. and Grossberg, G.T. (2017). Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics. Expert Rev. Neurother. 17: 17–32, https://doi.org/10.1080/14737175.2016.1200972.Search in Google Scholar PubMed

Efthymiou, A.G. and Goate, A.M. (2017). Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12: 43, https://doi.org/10.1186/s13024-017-0184-x.Search in Google Scholar PubMed PubMed Central

Elcioğlu, H.K., Aslan, E., Ahmad, S., Alan, S., Salva, E., Elcioglu, Ö.H., and Kabasakal, L. (2016). Tocilizumab’s effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer’s model. Mol. Cell. Biochem. 420: 21–28, https://doi.org/10.1007/s11010-016-2762-6.Search in Google Scholar PubMed

Ferretti, M.T. and Cuello, A.C. (2011). Does a pro-inflammatory process precede Alzheimer’s disease and mild cognitive impairment? Curr. Alzheimer Res. 8: 164–174, https://doi.org/10.2174/156720511795255982.Search in Google Scholar PubMed

Gambuzza, M.E., Sofo, V., Salmeri, F.M., Soraci, L., Marino, S., and Bramanti, P. (2014). Toll-like receptors in Alzheimer’s disease: a therapeutic perspective. CNS Neurol. Disord. - Drug Targets 13: 1542–1558, https://doi.org/10.2174/1871527313666140806124850.Search in Google Scholar PubMed

Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F., et al.. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553–1562, https://doi.org/10.1212/01.wnl.0000159740.16984.3c.Search in Google Scholar PubMed

Gold, M. and El Khoury, J. (2015). β-amyloid, microglia, and the inflammasome in Alzheimer’s disease. Semin. Immunopathol. 37: 607–611, https://doi.org/10.1007/s00281-015-0518-0.Search in Google Scholar PubMed PubMed Central

Gomez, W., Morales, R., Maracaja-Coutinho, V., Parra, V., and Nassif, M. (2020). Down syndrome and Alzheimer’s disease: common molecular traits beyond the amyloid precursor protein. Aging 12: 1011–1033, https://doi.org/10.18632/aging.102677.Search in Google Scholar

Griciuc, A., Patel, S., Federico, A.N., Choi, S.H., Innes, B.J., Oram, M.K., Cereghetti, G., Mcginty, D., Anselmo, A., Sadreyev, R.I., et al.. (2019). TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron 103: 820–835.e7, https://doi.org/10.1016/j.neuron.2019.06.010.Search in Google Scholar

Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E., Moore, K.J., and Golenbock, D.T. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9: 857–865, https://doi.org/10.1038/ni.1636.Search in Google Scholar

Hashemiaghdam, A. and Mroczek, M. (2020). Microglia heterogeneity and neurodegeneration: the emerging paradigm of the role of immunity in Alzheimer’s disease. J. Neuroimmunol. 341: 577185, https://doi.org/10.1016/j.jneuroim.2020.577185.Search in Google Scholar

Henderson, S.J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T.J., Appelkvist, P., Bogstedt, A., Steffen, A.C., Haupts, U., Tebbe, J., et al.. (2014). Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. Brain 137: 553–564, https://doi.org/10.1093/brain/awt308.Search in Google Scholar

Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., et al.. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14: 388–405, https://doi.org/10.1016/s1474-4422(15)70016-5.Search in Google Scholar

Heneka, M.T., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.C., et al.. (2013). NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493: 674–678, https://doi.org/10.1038/nature11729.Search in Google Scholar PubMed PubMed Central

Heppner, F.L., Ransohoff, R.M., and Becher, B. (2015). Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16: 358–372, https://doi.org/10.1038/nrn3880.Search in Google Scholar PubMed

Honig, L.S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al.. (2018). Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378: 321–330, https://doi.org/10.1056/nejmoa1705971.Search in Google Scholar

Hook, V.Y., Kindy, M., and Hook, G. (2008). Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J. Biol. Chem. 283: 7745–7753, https://doi.org/10.1074/jbc.m708362200.Search in Google Scholar

Hoskin, J.L., Sabbagh, M.N., Al-Hasan, Y., and Decourt, B. (2019). Tau immunotherapies for Alzheimer’s disease. Expet Opin. Invest. Drugs 28: 545–554, https://doi.org/10.1080/13543784.2019.1619694.Search in Google Scholar PubMed PubMed Central

Hull, M., Sadowsky, C., Arai, H., Le Prince Leterme, G., Holstein, A., Booth, K., Peng, Y., Yoshiyama, T., Suzuki, H., Ketter, N., et al.. (2017). Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer’s disease. Curr. Alzheimer Res. 14: 696–708, https://doi.org/10.2174/1567205014666170117101537.Search in Google Scholar PubMed PubMed Central

Iliff, J.J., Wang, M., Liao, Y., Plogg, B.A., Peng, W., Gundersen, G.A., Benveniste, H., Vates, G.E., Deane, R., Goldman, S.A., et al.. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4: 147ra111, https://doi.org/10.1126/scitranslmed.3003748.Search in Google Scholar PubMed PubMed Central

Iqbal, K., Liu, F., and Gong, C.X. (2018). Recent developments with tau-based drug discovery. Expet Opin. Drug Discov. 13: 399–410, https://doi.org/10.1080/17460441.2018.1445084.Search in Google Scholar PubMed

Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S.V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R.M., Tejera, D., et al.. (2019). NLRP3 inflammasome activation drives tau pathology. Nature 575: 669–673, https://doi.org/10.1038/s41586-019-1769-z.Search in Google Scholar PubMed PubMed Central

Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B.C., Christie, M.J., Napier, I.A., et al.. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142: 387–397, https://doi.org/10.1016/j.cell.2010.06.036.Search in Google Scholar PubMed

Jadhav, S., Avila, J., Schöll, M., Kovacs, G.G., Kövari, E., Skrabana, R., Evans, L.D., Kontsekova, E., Malawska, B., de Silva, R., et al.. (2019). A walk through tau therapeutic strategies. Acta Neuropathol. Commun. 7: 22, https://doi.org/10.1186/s40478-019-0664-z.Search in Google Scholar PubMed PubMed Central

Jiang, C., Li, G., Huang, P., Liu, Z., and Zhao, B. (2017). The gut microbiota and Alzheimer’s disease. J. Alzheim. Dis. 58: 1–15, https://doi.org/10.3233/jad-161141.Search in Google Scholar PubMed

Jones, R.S., Minogue, A.M., Connor, T.J., and Lynch, M.A. (2013). Amyloid-β-induced astrocytic phagocytosis is mediated by CD36, CD47 and RAGE. J. Neuroimmune Pharmacol. 8: 301–311, https://doi.org/10.1007/s11481-012-9427-3.Search in Google Scholar PubMed

Joo, Y., Kim, H.S., Woo, R.S., Park, C.H., Shin, K.Y., Lee, J.P., Chang, K.A., Kim, S., and Suh, Y.H. (2006). Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer’s disease models. Mol. Pharmacol. 69: 76–84, https://doi.org/10.1124/mol.105.015206.Search in Google Scholar PubMed

Jordan, F., Quinn, T.J., McGuinness, B., Passmore, P., Kelly, J.P., Tudur Smith, C., Murphy, K., and Devane, D. (2020). Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst. Rev. 4: Cd011459, https://doi.org/10.1002/14651858.CD011459.pub2.Search in Google Scholar PubMed PubMed Central

Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T.K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al.. (2017). A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169: 1276–1290.e17, https://doi.org/10.1016/j.cell.2017.05.018.Search in Google Scholar PubMed

Ketter, N., Liu, E., Di, J., Honig, L.S., Lu, M., Novak, G., Werth, J., Leprince Leterme, G., Shadman, A., and Brashear, H.R. (2016). A randomized, double-blind, phase 2 study of the effects of the vaccine vanutide cridificar with QS-21 adjuvant on immunogenicity, safety and amyloid imaging in patients with mild to moderate Alzheimer’s disease. J. Prev. Alzheimer’s Dis. 3: 192–201, https://doi.org/10.14283/jpad.2016.118.Search in Google Scholar PubMed

Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M., and Diamond, M.I. (2012). Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287: 19440–19451, https://doi.org/10.1074/jbc.m112.346072.Search in Google Scholar PubMed PubMed Central

Kinney, J.W., Bemiller, S.M., Murtishaw, A.S., Leisgang, A.M., Salazar, A.M., and Lamb, B.T. (2018). Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dementia 4: 575–590, https://doi.org/10.1016/j.trci.2018.06.014.Search in Google Scholar PubMed PubMed Central

Kitazawa, M., Cheng, D., Tsukamoto, M.R., Koike, M.A., Wes, P.D., Vasilevko, V., Cribbs, D.H., and Laferla, F.M. (2011). Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model. J. Immunol. 187: 6539–6549, https://doi.org/10.4049/jimmunol.1100620.Search in Google Scholar PubMed PubMed Central

Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al.. (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566–581.e9, https://doi.org/10.1016/j.immuni.2017.08.008.Search in Google Scholar PubMed PubMed Central

Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S., and Bernabei, R. (2003). Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am. J. Geriatr. Psychiatr. 11: 179–185, https://doi.org/10.1097/00019442-200303000-00008.Search in Google Scholar

La Porte, S.L., Bollini, S.S., Lanz, T.A., Abdiche, Y.N., Rusnak, A.S., Ho, W.H., Kobayashi, D., Harrabi, O., Pappas, D., Mina, E.W., et al.. (2012). Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. J. Mol. Biol. 421: 525–536, https://doi.org/10.1016/j.jmb.2011.11.047.Search in Google Scholar PubMed

Lee, H.G., Casadesus, G., Zhu, X., Takeda, A., Perry, G., and Smith, M.A. (2004). Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann. N. Y. Acad. Sci. 1019: 1–4, https://doi.org/10.1196/annals.1297.001.Search in Google Scholar PubMed

Lee, H.G., Zhu, X., Castellani, R.J., Nunomura, A., Perry, G., and Smith, M.A. (2007). Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J. Pharmacol. Exp. Therapeut. 321: 823–829, https://doi.org/10.1124/jpet.106.114009.Search in Google Scholar PubMed

Lee, H.G., Zhu, X., Nunomura, A., Perry, G., and Smith, M.A. (2006). Amyloid beta: the alternate hypothesis. Curr. Alzheimer Res. 3: 75–80, https://doi.org/10.2174/156720506775697124.Search in Google Scholar PubMed

Lee, J.D., Coulthard, L.G., and Woodruff, T.M. (2019). Complement dysregulation in the central nervous system during development and disease. Semin. Immunol. 45: 101340, https://doi.org/10.1016/j.smim.2019.101340.Search in Google Scholar PubMed

Lemere, C.A. (2013). Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol. Neurodegener. 8: 36, https://doi.org/10.1186/1750-1326-8-36.Search in Google Scholar PubMed PubMed Central

Lemere, C.A. and Masliah, E. (2010). Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol. 6: 108–119, https://doi.org/10.1038/nrneurol.2009.219.Search in Google Scholar PubMed PubMed Central

Leng, F. and Edison, P. (2020). Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17: 157–172.10.1038/s41582-020-00435-ySearch in Google Scholar PubMed

Lewcock, J.W., Schlepckow, K., di Paolo, G., Tahirovic, S., Monroe, K.M., and Haass, C. (2020). Emerging microglia biology defines novel therapeutic approaches for Alzheimer’s disease. Neuron 108: 801–821, https://doi.org/10.1016/j.neuron.2020.09.029.Search in Google Scholar PubMed

Li, Y., Liu, L., Barger, S.W., and Griffin, W.S. (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23: 1605–1611, https://doi.org/10.1523/jneurosci.23-05-01605.2003.Search in Google Scholar

Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., Bennett, M.L., Munch, A.E., Chung, W.S., Peterson, T.C., et al.. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541: 481–487, https://doi.org/10.1038/nature21029.Search in Google Scholar PubMed PubMed Central

Lin, L., Zheng, L.J., and Zhang, L.J. (2018). Neuroinflammation gut microbiome, and Alzheimer’s disease. Mol. Neurobiol. 55: 8243–8250, doi:https://doi.org/10.1007/s12035-018-0983-2.Search in Google Scholar PubMed

Liu, J., Yang, B., Ke, J., Li, W., and Suen, W.C. (2016). Antibody-based drugs and approaches against amyloid-β species for Alzheimer’s disease immunotherapy. Drugs Aging 33: 685–697, https://doi.org/10.1007/s40266-016-0406-x.Search in Google Scholar

Logovinsky, V., Satlin, A., Lai, R., Swanson, C., Kaplow, J., Osswald, G., Basun, H., and Lannfelt, L. (2016). Safety and tolerability of BAN2401--a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer’s Res. Ther. 8: 14, https://doi.org/10.1186/s13195-016-0181-2.Search in Google Scholar

Lyketsos, C.G., Breitner, J.C., Green, R.C., Martin, B.K., Meinert, C., Piantadosi, S., and Sabbagh, M. (2007). Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68: 1800–1808, https://doi.org/10.1212/01.wnl.0000260269.93245.d2.Search in Google Scholar

Maphis, N., Xu, G., Kokiko-Cochran, O.N., Jiang, S., Cardona, A., Ransohoff, R.M., Lamb, B.T., and Bhaskar, K. (2015). Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 138: 1738–1755, https://doi.org/10.1093/brain/awv081.Search in Google Scholar

Momtazmanesh, S., Perry, G., and Rezaei, N. (2020). Toll-like receptors in Alzheimer’s disease. J. Neuroimmunol. 348: 577362, https://doi.org/10.1016/j.jneuroim.2020.577362.Search in Google Scholar

Mondragón-Rodríguez, S., Trillaud-Doppia, E., Dudilot, A., Bourgeois, C., Lauzon, M., Leclerc, N., and Boehm, J. (2012). Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 287: 32040–32053, https://doi.org/10.1074/jbc.m112.401240.Search in Google Scholar

Mori, H., Takio, K., Ogawara, M., and Selkoe, D.J. (1992). Mass spectrometry of purified amyloid beta protein in Alzheimer’s disease. J. Biol. Chem. 267: 17082–17086, https://doi.org/10.1016/s0021-9258(18)41896-0.Search in Google Scholar

Muhs, A., Hickman, D.T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., Van der Auwera, I., van Leuven, F., Sugawara, M., Weingertner, M.C., et al.. (2007). Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 104: 9810–9815, https://doi.org/10.1073/pnas.0703137104.Search in Google Scholar PubMed PubMed Central

Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B.L., Rajendiran, T.M., and Núñez, G. (2013). K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38: 1142–1153, https://doi.org/10.1016/j.immuni.2013.05.016.Search in Google Scholar PubMed PubMed Central

Muntimadugu, E., Dhommati, R., Jain, A., Challa, V.G., Shaheen, M., and Khan, W. (2016). Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease. Eur. J. Pharmaceut. Sci. 92: 224–234, https://doi.org/10.1016/j.ejps.2016.05.012.Search in Google Scholar PubMed

Murphy, N., Grehan, B., and Lynch, M.A. (2014). Glial uptake of amyloid beta induces NLRP3 inflammasome formation via cathepsin-dependent degradation of NLRP10. NeuroMolecular Med. 16: 205–215, https://doi.org/10.1007/s12017-013-8274-6.Search in Google Scholar PubMed

Newcombe, E.A., Camats-Perna, J., Silva, M.L., Valmas, N., Huat, T.J., and Medeiros, R. (2018). Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J. Neuroinflammation 15: 276, https://doi.org/10.1186/s12974-018-1313-3.Search in Google Scholar PubMed PubMed Central

Nicoll, J.A.R., Buckland, G.R., Harrison, C.H., Page, A., Harris, S., Love, S., Neal, J.W., Holmes, C., and Boche, D. (2019). Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease. Brain 142: 2113–2126, https://doi.org/10.1093/brain/awz142.Search in Google Scholar PubMed PubMed Central

Novak, P., Kontsekova, E., Zilka, N., and Novak, M. (2018). Ten years of Tau-targeted immunotherapy: the path walked and the roads ahead. Front. Neurosci. 12: 798, https://doi.org/10.3389/fnins.2018.00798.Search in Google Scholar PubMed PubMed Central

Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al.. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46–54, https://doi.org/10.1212/01.wnl.0000073623.84147.a8.Search in Google Scholar PubMed

Ozben, T. and Ozben, S. (2019). Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin. Biochem. 72: 87–89, https://doi.org/10.1016/j.clinbiochem.2019.04.001.Search in Google Scholar PubMed

Panza, F., Lozupone, M., Seripa, D., and Imbimbo, B.P. (2019). Amyloid-β immunotherapy for alzheimer disease: is it now a long shot? Ann. Neurol. 85: 303–315, https://doi.org/10.1002/ana.25410.Search in Google Scholar PubMed

Parkhurst, C.N., Yang, G., Ninan, I., Savas, J.N., Yates, J.R.3rd, Lafaille, J.J., Hempstead, B.L., Littman, D.R., and Gan, W.B. (2013). Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155: 1596–1609, https://doi.org/10.1016/j.cell.2013.11.030.Search in Google Scholar PubMed PubMed Central

Parvathenani, L.K., Tertyshnikova, S., Greco, C.R., Roberts, S.B., Robertson, B., and Posmantur, R. (2003). P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer’s disease. J. Biol. Chem. 278: 13309–13317, https://doi.org/10.1074/jbc.m209478200.Search in Google Scholar

Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., and Rossini, P.M. (2009). A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin. Exp. Res. 21: 102–110, https://doi.org/10.1007/bf03325217.Search in Google Scholar PubMed

Prinz, M. and Priller, J. (2014). Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15: 300–312, https://doi.org/10.1038/nrn3722.Search in Google Scholar PubMed

Qureshi, I.A., Tirucherai, G., Ahlijanian, M.K., Kolaitis, G., Bechtold, C., and Grundman, M. (2018). A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer’s Dementia 4: 746–755, https://doi.org/10.1016/j.trci.2018.10.007.Search in Google Scholar PubMed PubMed Central

Regland, B. and McCaddon, A. (2019). Alzheimer’s amyloidopathy: an alternative aspect. J. Alzheim. Dis. 68: 483–488, https://doi.org/10.3233/jad-181007.Search in Google Scholar

Rogers, M.B. (2017). Treating tau: finally, clinical candidates are stepping into the ring [Online]. Alzforum, Available at: http://www.alzforum.org/news/conference-coverage/treatingtau-finally-clinical-candidates-are-stepping-ring (Accessed February 2021).Search in Google Scholar

Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., and Abramsky, O. (2006). Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63: 1459–1467, https://doi.org/10.1001/archneur.63.10.1459.Search in Google Scholar PubMed

Rusanen, M., Ngandu, T., Laatikainen, T., Tuomilehto, J., Soininen, H., and Kivipelto, M. (2013). Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. Curr. Alzheimer Res. 10: 549–555, https://doi.org/10.2174/1567205011310050011.Search in Google Scholar PubMed

Sala Frigerio, C., Wolfs, L., Fattorelli, N., Thrupp, N., Voytyuk, I., Schmidt, I., Mancuso, R., Chen, W.T., Woodbury, M.E., Srivastava, G., et al.. (2019). The major risk factors for Alzheimer’s disease: age, sex, and genes modulate the microglia response to Aβ plaques. Cell Rep. 27: 1293–1306.e6, https://doi.org/10.1016/j.celrep.2019.03.099.Search in Google Scholar PubMed PubMed Central

Salloway, S., Honigberg, L.A., Cho, W., Ward, M., Friesenhahn, M., Brunstein, F., Quartino, A., Clayton, D., Mortensen, D., Bittner, T., et al.. (2018). Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimer’s Res. Ther. 10: 96, https://doi.org/10.1186/s13195-018-0424-5.Search in Google Scholar PubMed PubMed Central

Sánchez-Sarasúa, S., Fernández-Perez, I., and Espinosa-Fernández, V. (2020). Can we treat neuroinflammation in Alzheimer’s disease? Int. J. Mol. Sci. 21: 8751.10.3390/ijms21228751Search in Google Scholar PubMed PubMed Central

Saresella, M., La Rosa, F., Piancone, F., Zoppis, M., Marventano, I., Calabrese, E., Rainone, V., Nemni, R., Mancuso, R., and Clerici, M. (2016). The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease. Mol. Neurodegener. 11: 23, https://doi.org/10.1186/s13024-016-0088-1.Search in Google Scholar PubMed PubMed Central

Schroder, K. and Tschopp, J. (2010). The inflammasomes. Cell 140: 821–832, https://doi.org/10.1016/j.cell.2010.01.040.Search in Google Scholar PubMed

Selkoe, D.J. and Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8: 595–608, https://doi.org/10.15252/emmm.201606210.Search in Google Scholar PubMed PubMed Central

Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P.H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al.. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537: 50–56, https://doi.org/10.1038/nature19323.Search in Google Scholar PubMed

Sheng, W.S., Hu, S., Feng, A., and Rock, R.B. (2013). Reactive oxygen species from human astrocytes induced functional impairment and oxidative damage. Neurochem. Res. 38: 2148–2159, https://doi.org/10.1007/s11064-013-1123-z.Search in Google Scholar PubMed PubMed Central

Streit, W.J., Braak, H., Xue, Q.S., and Bechmann, I. (2009). Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 118: 475–485, https://doi.org/10.1007/s00401-009-0556-6.Search in Google Scholar PubMed PubMed Central

Subaiea, G.M., Ahmed, A.H., Adwan, L.I., and Zawia, N.H. (2015). Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid. J. Alzheim. Dis. 43: 425–433, https://doi.org/10.3233/JAD-132726.Search in Google Scholar PubMed

Szekely, C.A., Green, R.C., Breitner, J.C., Østbye, T., Beiser, A.S., Corrada, M.M., Dodge, H.H., Ganguli, M., Kawas, C.H., Kuller, L.H., et al.. (2008). No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70: 2291–2298, https://doi.org/10.1212/01.wnl.0000313933.17796.f6.Search in Google Scholar PubMed PubMed Central

Taipa, R., Das Neves, S.P., Sousa, A.L., Fernandes, J., Pinto, C., Correia, A.P., Santos, E., Pinto, P.S., Carneiro, P., Costa, P., et al.. (2019). Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol. Aging 76: 125–132, https://doi.org/10.1016/j.neurobiolaging.2018.12.019.Search in Google Scholar PubMed

Tanzi, R.E. and Bertram, L. (2005). Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120: 545–555, https://doi.org/10.1016/j.cell.2005.02.008.Search in Google Scholar PubMed

Thal, D.R., Rub, U., Orantes, M., and Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791–1800, https://doi.org/10.1212/wnl.58.12.1791.Search in Google Scholar PubMed

Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M.P., Reis, P., Hickman, D.T., Adolfsson, O., Chuard, N., Ndao, D.M., et al.. (2013). Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One 8: e72301, https://doi.org/10.1371/journal.pone.0072301.Search in Google Scholar PubMed PubMed Central

Tong, L., Prieto, G.A., Kramár, E.A., Smith, E.D., Cribbs, D.H., Lynch, G., and Cotman, C.W. (2012). Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J. Neurosci. 32: 17714–17724, https://doi.org/10.1523/jneurosci.1253-12.2012.Search in Google Scholar

United Neuroscience (2019). United neuroscience announces positive top-line results from phase 2a clinical study of UB-311 vaccine in patients with Alzheimer’s disease [Online], Available at: https://www.prnewswire.com/news-releases/united-neuroscience-announces-positive-top-line-results-from-phase-2a-clinical-study-of-ub-311-vaccine-in-patients-with-alzheimers-disease-300779315.html (Accessed 9 July 2021).Search in Google Scholar

Ultsch, M., Li, B., Maurer, T., Mathieu, M., Adolfsson, O., Muhs, A., Pfeifer, A., Pihlgren, M., Bainbridge, T.W., Reichelt, M., et al.. (2016). Structure of crenezumab complex with Aβ shows loss of β-hairpin. Sci. Rep. 6: 39374, https://doi.org/10.1038/srep39374.Search in Google Scholar PubMed PubMed Central

Vandenberghe, R., Rinne, J.O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J.B., Hill, D., et al.. (2016). Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer’s Res. Ther. 8: 18, https://doi.org/10.1186/s13195-016-0189-7.Search in Google Scholar PubMed PubMed Central

VandeVrede, L., Boxer, A.L., and Polydoro, M. (2020). Targeting tau: clinical trials and novel therapeutic approaches. Neurosci. Lett. 731: 134919, https://doi.org/10.1016/j.neulet.2020.134919.Search in Google Scholar PubMed

van Dyck, C.H. (2018). Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol. Psychiatr. 83: 311–319, https://doi.org/10.1016/j.biopsych.2017.08.010.Search in Google Scholar PubMed PubMed Central

Veerhuis, R., Van der Valk, P., Janssen, I., Zhan, S.S., van Nostrand, W.E., and Eikelenboom, P. (1995). Complement activation in amyloid plaques in Alzheimer’s disease brains does not proceed further than C3. Virchows Arch. 426: 603–610, https://doi.org/10.1007/bf00192116.Search in Google Scholar PubMed

Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al.. (2011). Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 69: 181–192, https://doi.org/10.1002/ana.22248.Search in Google Scholar PubMed PubMed Central

Violet, M., Delattre, L., Tardivel, M., Sultan, A., Chauderlier, A., Caillierez, R., Talahari, S., Nesslany, F., Lefebvre, B., Bonnefoy, E., et al.. (2014). A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front. Cell. Neurosci. 8: 84, https://doi.org/10.3389/fncel.2014.00084.Search in Google Scholar PubMed PubMed Central

Vlad, S.C., Miller, D.R., Kowall, N.W., and Felson, D.T. (2008). Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70: 1672–1677, https://doi.org/10.1212/01.wnl.0000311269.57716.63.Search in Google Scholar PubMed PubMed Central

Wang, C.Y., Finstad, C.L., Walfield, A.M., Sia, C., Sokoll, K.K., Chang, T.Y., Fang, X.D., Hung, C.H., Hutter-Paier, B., and Windisch, M. (2007). Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer’s disease. Vaccine 25: 3041–3052, https://doi.org/10.1016/j.vaccine.2007.01.031.Search in Google Scholar PubMed

Wang, C.Y., Wang, P.N., Chiu, M.J., Finstad, C.L., Lin, F., Lynn, S., Tai, Y.H., De Fang, X., Zhao, K., Hung, C.H., et al.. (2017). UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer’s disease. Alzheimer’s Dementia 3: 262–272, https://doi.org/10.1016/j.trci.2017.03.005.Search in Google Scholar PubMed PubMed Central

West, T., Hu, Y., Verghese, P.B., Bateman, R.J., Braunstein, J.B., Fogelman, I., Budur, K., Florian, H., Mendonca, N., and Holtzman, D.M. (2017). Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J. Prev. Alzheimer’s Dis. 4: 236–241, https://doi.org/10.14283/jpad.2017.36.Search in Google Scholar PubMed

White, C.S., Lawrence, C.B., Brough, D., and Rivers-Auty, J. (2017). Inflammasomes as therapeutic targets for Alzheimer’s disease. Brain Pathol. 27: 223–234, https://doi.org/10.1111/bpa.12478.Search in Google Scholar PubMed PubMed Central

Wirenfeldt, M., Babcock, A.A., and Vinters, H.V. (2011). Microglia - insights into immune system structure, function, and reactivity in the central nervous system. Histol. Histopathol. 26: 519–530, https://doi.org/10.14670/HH-26.519.Search in Google Scholar PubMed

Wu, A.G., Zhou, X.G., Qiao, G., Yu, L., Tang, Y., Yan, L., Qiu, W.Q., Pan, R., Yu, C.L., Law, B.Y., et al.. (2021). Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. Ageing Res. Rev. 65: 101202, https://doi.org/10.1016/j.arr.2020.101202.Search in Google Scholar PubMed

Yamamoto, M., Kiyota, T., Walsh, S.M., Liu, J., Kipnis, J., and Ikezu, T. (2008). Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J. Immunol. 181: 3877–3886, https://doi.org/10.4049/jimmunol.181.6.3877.Search in Google Scholar PubMed PubMed Central

Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., Diamond, M.I., and Holtzman, D.M. (2015). Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2: 278–288, https://doi.org/10.1002/acn3.176.Search in Google Scholar PubMed PubMed Central

Yang, R., Duan, J., Luo, F., Tao, P., and Hu, C. (2020). IL-6, IL-8 and IL-10 polymorphisms may impact predisposition of Alzheimer’s disease: a meta-analysis. Acta Neurol. Belg., https://doi.org/10.1007/s13760-020-01369-4.Search in Google Scholar PubMed

Zhang, Y.Y., Fan, Y.C., Wang, M., Wang, D., and Li, X.H. (2013). Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease. Clin. Interv. Aging 8: 103–110, https://doi.org/10.2147/CIA.S40405.Search in Google Scholar PubMed PubMed Central